Non-peptide GLP-1 agonist

Orforglipron is the first GLP-1 receptor agonist that is not a peptide. That matters for a practical reason: a small molecule can be made by ordinary chemical synthesis rather than fermentation, and swallowed as a normal tablet with no food or water restrictions - unlike oral semaglutide, which needs an absorption enhancer and an empty stomach. In ATTAIN-1, 72 weeks of 36 mg daily gave a mean 11.2% weight loss against 2.1% on placebo; in ATTAIN-2, in people with obesity and type 2 diabetes, 9.6% against 2.5%. That places it below injected semaglutide and well below tirzepatide on weight, and roughly where oral semaglutide sits - while being far easier to take and, in principle, far easier to manufacture at scale.